로딩 중…
지수 로딩 중…
HLB bioStep Co.,Ltd.
278650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,455-2.00%
2026-09-18
Financials
Valuation Metrics
HLB bioStep Co.,Ltd.'s Market Cap is ₩428B. At end of 2025 it was ₩1267B. Ranked #1875 of 2,421 in KR market (top 77%), #1160 of 1,640 on KOSDAQ (top 71%), #200 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 42.80B KRW | KR#1,875/2,421 Sec#200/231 |
| Revenue | 72.15B KRW | KR#1,604/2,421 Sec#105/231 |
| Net Income | -19.48B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 145.77B KRW | KR#1,523/2,421 Sec#114/231 |
| Net Assets | 96.61B KRW | KR#1,444/2,421 Sec#115/231 |
| Employees | 167 | KR#1,229/2,421 Sec#101/231 |
| Value | ||
| P/B | 0.44x | KR#673/2,421 Sec#27/231 |
| P/S | 0.59x | KR#1,026/2,421 Sec#47/231 |
| FCF Yield | 2.60% | KR#1,015/2,421 Sec#64/231 |
| Profitability | ||
| ROE | -20.17% | KR#2,096/2,421 Sec#163/231 |
| ROA | -13.37% | KR#2,165/2,421 Sec#167/231 |
| Op. Margin | -8.68% | KR#1,961/2,421 Sec#133/231 |
| Revenue Growth | 9.27% | KR#943/2,421 Sec#92/231 |
| Financial Health | ||
| Debt Ratio | 50.88% | KR#971/2,421 Sec#112/231 |
| Total Debt | 30.11B KRW | KR#1,227/2,421 Sec#95/231 |
| FCF | 1.11B KRW | KR#1,140/2,421 Sec#83/231 |
| Cash | 33.32B KRW | KR#941/2,421 Sec#62/231 |
| Current Ratio | 1.27x | KR#1,426/2,421 Sec#150/231 |
| Dividend | ||
| Div. Growth | 35.17% | KR#321/2,421 Sec#16/231 |
| Performance | ||
| 1Y Return | -64.03% | KR#2,253/2,421 Sec#211/231 |
| 1M Return | 2.29% | KR#995/2,421 Sec#73/231 |
| From 52W High | -75.69% | KR#2,298/2,421 Sec#203/231 |
| 1Y MDD | -80.97% | KR#2,311/2,421 Sec#213/231 |
| Trading | ||
| Volume | 78,775 shares | KR#903/2,421 Sec#94/231 |
| Trading Value | 195.1M KRW | KR#1,282/2,421 Sec#130/231 |
| Foreign Own. | 0.52% | KR#2,205/2,421 Sec#211/231 |
| Per Share | ||
| EPS | -1,118 KRW | KR—/2,421 Sec—/231 |
| BPS | 5,542 KRW | KR#1,414/2,421 Sec#101/231 |
Company Info
동사는 2012년 설립된 비임상 CRO 전문기업으로 코스닥 상장 후 2024년 GLP 독성시험 전문기업 HLB바이오코드를 인수하여 종속회사로 편입함. 신약 후보물질의 유효성과 안전성 검증을 주력으로, HLB바이오코드 인수로 GLP 독성시험까지 원스톱 서비스 제공이 가능해짐. 질환동물 유발 및 관리 특화 기술력으로 중대동물 실험에서 독보적 지위 확보, HLB그룹과 AI 신약개발 플랫폼 구축 등 신사업을 추진하고 있음. HLB바이오스텝는 2012년에 설립되었으며 인천광역시 연수구에 본사를 두고 있습니다.